EUVIMEDEUVIMED entdecken
EvaluationsstudieOpen Access · CC BY 4.0

Evaluation of a high-throughput Candidozyma auris assay for use on the cobas 5800/6800/8800 omni Utility Channel

Jeffrey Alexander iD, Natacha Martins-Sorenson iD, Arrash Moghaddasi, Andrew T Hill, Jody Harris, Stephen McCune, Erin Gick, YanChun Zhu, Sudha Chaturvedi iD, Michael Lewinski, Kyle C Cady iD

Microbiology Spectrum · 2025

DOI: 10.1128/spectrum.00254-25 ↗

Kurz gefasst

Evaluationsstudie in der Zeitschrift Microbiology Spectrum, 2025. Verfasst von Jeffrey Alexander und 10 weiteren Autor:innen. Beteiligte Einrichtung: Roche Molecular Systems, Pleasanton, California, USA. Hauptthemen laut MEDLINE: High-Throughput Screening Assays, Molecular Diagnostic Techniques, Candida auris, Mycoses. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Candidozyma auris (formerly known as Candida auris ) is an emerging worldwide fungal pathogen associated with difficult-to-treat nosocomial infections. Screening of patients for colonization is a recommended strategy to track and prevent hospital spread and outbreaks caused by C. auris . To facilitate this, a high-throughput (HTP) assay with a short turnaround time and minimal manual processing has significant value. Here, we present ongoing research on the detection of C. auris by direct testing of nasal/axilla/groin swab samples using the HTP cobas 5800/6800/8800 family of systems that has the ability to process up to 1,056 samples in an 8 h shift. Based on testing of 200 surveillance swab samples, the cobas C. auris Utility Channel (UC) assay demonstrated 94% accuracy, 91% positive percent agreement, and 98% negative percent agreement when compared to an established nucleic acid amplification test (NAAT) (BD MAX Open System assay). In a secondary analysis of 159 out of the 200 samples, the assay was compared to standard-of-care culture results with an observed 95% accuracy, 92% sensitivity, and 90% specificity. The cobas C. auris UC assay was inclusive for clades I–V and exclusive to 15 other closely related fungal species based on wet lab testing. The data presented originated from internally conducted studies performed for research purposes. The cobas C. auris UC assay is not approved for in vitro diagnostic use. IMPORTANCE C. auris is an emerging multidrug-resistant fungal pathogen and considered a global public health threat. Rapid detection and identification of C. auris is critical for hospital infection prevention and control and outbreak surveillance. The standard-of-care testing for C. auris involves culture-based methods with a long turnaround time. A rapid assay with higher throughput and quicker turnaround time can facilitate measures to minimize potential spread and prevent outbreaks within healthcare facilities. In the internal research study presented here, we evaluated a fully automated HTP C. auris assay for direct testing of nasal/axilla/groin swab samples on a commercially available platform and compared the results to an established NAAT assay.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

High-Throughput Screening AssaysMolecular Diagnostic TechniquesCandida aurisMycosesHumansSensitivity and SpecificityNucleic Acid Amplification TechniquesCross InfectionCandidiasis

Stichwörter der Autor:innen

Candidozymadiagnosticshospital infections

Autor:innen und Institutionen

  • Roche Molecular Systems, Pleasanton, California, USA.
  • Roche Molecular Systems, Santa Clara, California, USA.
  • Roche Diagnostics Corporation, Indianapolis, Indiana, USA.
  • Mycology Laboratory, Wadsworth Center, New York State Department of Health, Albany, New York, USA.

ORCID-Profile: Jeffrey Alexander, Natacha Martins-Sorenson, Sudha Chaturvedi, Kyle C Cady

Zitieren

APA

Alexander, J., Martins-Sorenson, N., Moghaddasi, A., Hill, A. T., Harris, J., McCune, S., Gick, E., Zhu, Y., Chaturvedi, S., Lewinski, M., & Cady, K. C. (2025). Evaluation of a high-throughput Candidozyma auris assay for use on the cobas 5800/6800/8800 omni Utility Channel. Microbiology Spectrum. https://doi.org/10.1128/spectrum.00254-25

Vancouver

Alexander J, Martins-Sorenson N, Moghaddasi A, Hill AT, Harris J, McCune S, et al. Evaluation of a high-throughput Candidozyma auris assay for use on the cobas 5800/6800/8800 omni Utility Channel. Microbiology Spectrum. 2025. doi:10.1128/spectrum.00254-25

BibTeX
@article{Alexander2025,
  author = {Alexander, Jeffrey and Martins-Sorenson, Natacha and Moghaddasi, Arrash and Hill, Andrew T and Harris, Jody and McCune, Stephen and Gick, Erin and Zhu, YanChun and Chaturvedi, Sudha and Lewinski, Michael and Cady, Kyle C},
  title = {Evaluation of a high-throughput Candidozyma auris assay for use on the cobas 5800/6800/8800 omni Utility Channel},
  journal = {Microbiology Spectrum},
  year = {2025},
  doi = {10.1128/spectrum.00254-25}
}
Kostenlos starten →